SCHEMBL23214979

SCHEMBL23214979

COc1cc(Cl)c(Cl)cc1C(Br)C1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.45
PDE4A P27815 2/20 0.45
PDE4C Q08493 2/20 0.45
PDE4D Q08499 2/20 0.45
MMP13 P45452 4/20 0.44
STS P08842 3/20 0.44
DPP4 P27487 1/20 0.43
MMP1 P03956 3/20 0.43
MMP3 P08254 3/20 0.43
MMP7 P09237 3/20 0.43
MMP9 P14780 3/20 0.43
MMP8 P22894 3/20 0.43
MMP2 P08253 2/20 0.43
ALDH1A1 P00352 3/20 0.42
MAPT P10636 2/20 0.42
MAPK1 P28482 2/20 0.42
NPC1 O15118 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29745344 1.00 PDE4B (0.45) PDE4BPDE4APDE4CPDE4DMMP13
SCHEMBL29745717 0.88 EED (0.49) PDE4BPDE4APDE4CPDE4DMMP13
SCHEMBL25015757 0.88 PDE4B (0.45) PDE4BPDE4APDE4CPDE4DMMP13
SCHEMBL23216535 0.88 EED (0.49) PDE4BPDE4APDE4CPDE4DMMP13
SCHEMBL29745548 0.87 DPP4 (0.51) PDE4BPDE4APDE4CPDE4DMMP13
SCHEMBL23216646 0.87 DPP4 (0.51) PDE4BPDE4APDE4CPDE4DMMP13
SCHEMBL29745220 0.86 DPP4 (0.45) PDE4BPDE4APDE4CPDE4DMMP13
SCHEMBL23215568 0.86 DPP4 (0.45) PDE4BPDE4APDE4CPDE4DMMP13
SCHEMBL23215922 0.85 QDPR (0.43) PDE4BDPP4ALDH1A1RAB9AEZH2
SCHEMBL29745261 0.85 QDPR (0.43) PDE4BDPP4ALDH1A1RAB9AEZH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230023559-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2023-01-26 US disclosed
WO-2021071806-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed
WO-2021071806-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230023559-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNJ2, KCNA3, KCNH3 PDE4B 1668/4885PDE4A 1706/4885PDE4C 1759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.